Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fosun’s Gland Acquisition Faces Indian Wall?

Executive Summary

Chinese group Fosun’s landmark buyout of Gland Pharma appears less likely to go through in India, at least for now, though some experts claim that the deal has always been a tricky one from the Indian standpoint. Indo-China border tensions are unlikely to make things any easier.


Related Content

Deal Watch: Takeda Continues Transaction Spree With Four More Deals
China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions
Fosun On Course To Full Indian Clearance For Gland Buyout


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts